|
Status |
Public on Nov 10, 2015 |
Title |
LGWU102569-1036382WU |
Sample type |
RNA |
|
|
Source name |
Breast Tumor CALGB 102569
|
Organism |
Homo sapiens |
Characteristics |
gender: female tissue type: Breast Tumor fixative: Formalin-Fixed Paraffin Embedded Tissue
|
Biomaterial provider |
CALGB
|
Treatment protocol |
The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.
|
Growth protocol |
N/A
|
Extracted molecule |
total RNA |
Extraction protocol |
http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf
|
Label |
NA
|
Label protocol |
See manufacturer's website http://www.nanostring.com for procedures
|
|
|
Hybridization protocol |
See manufacturer's website http://www.nanostring.com for procedures.
|
Scan protocol |
See manufacturer's website http://www.nanostring.com for procedures. Digital Analyzer was set to scan at 1155 FOV (fields of view)
|
Data processing |
See manufacturer's website http://www.nanostring.com. Raw data was background subtracted and normalized to the geometric mean of the housekeepers.
|
|
|
Submission date |
Nov 09, 2015 |
Last update date |
Nov 10, 2015 |
Contact name |
Sherri R Davies |
E-mail(s) |
[email protected]
|
Phone |
3147473073
|
Organization name |
Washington University
|
Street address |
4950 Parkview Place
|
City |
Saint Louis |
State/province |
MO |
ZIP/Postal code |
63110 |
Country |
USA |
|
|
Platform ID |
GPL21114 |
Series (1) |
GSE74821 |
Gene expression analysis of CALGB 9741 patient tumor samples using the nCounter RUO-PAM50 signature |
|